Independent
Tenure on this board
5.5 yrs
Also a director at
Scholar Rock Holding Corp (SRRK)Vtv Therapeutics Inc (VTVT)Alumis Inc (ALMS)Kalaris Therapeutics Inc (KLRS)
Meeting calendar
MLYS · Annual meeting · Thursday, May 21, 2026
Mineralys Therapeutics Inc
3 nominees · 2 ballot items.
Elect three Class III directors to serve three-year terms and ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year.
Market cap
$2.2B
1Y TSR
+90.5%
Board grade
C
Record date
Mar 25, 2026
Filing
DEF 14A
Meeting concluded · May 21, 2026
Follow how the vote landed and what changed on Mineralys Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Directors
ManagementBoard: FORTo elect three directors (Srinivas Akkaraju, M.D., Ph.D.; Brian Taylor Slingsby, M.D., Ph.D., M.P.H.; and Daphne Karydas) as Class III directors to serve three-year terms expiring at the 2029 annual meeting.
- 2
Ratification of Selection of Independent Registered Public Accounting Firm
ManagementBoard: FORTo ratify the appointment of Ernst & Young LLP as Mineralys Therapeutics, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
7.1 yrs
Independent
Tenure on this board
2.8 yrs
Also a director at
Compass Pathways PLC (CMPS)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Catalys Pacific, LLC | 9.6% | 7,903,838 | $214M |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 9.3% | 7,692,750 | $208M |
| 3 | Samsara BioCapital, LLC | 7.1% | 5,871,018 | $159M |
| 4 | FMR LLC | 5.1% | 4,240,197 | $115M |
| 5 | STATE STREET CORP | 3.6% | 2,935,940 | $80M |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 3.4% | 2,838,587 | $77M |
| 7 | Caligan Partners LPActivist | 3.4% | 2,772,654 | $75M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 3.0% | 2,454,363 | $66M |
| 9 | BlackRock, Inc. | 2.9% | 2,360,917 | $64M |
| 10 | Laurion Capital Management LP | 2.7% | 2,232,040 | $60M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Mineralys Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.6B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.6B
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.5B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.6B
Reference
Frequently asked questions
- When is the Mineralys Therapeutics Inc 2026 annual meeting?
- Mineralys Therapeutics Inc (MLYS) holds its 2026 annual shareholder meeting on Thursday, May 21, 2026.
- What is the record date for the Mineralys Therapeutics Inc 2026 meeting?
- The record date for the Mineralys Therapeutics Inc 2026 meeting is Wednesday, March 25, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Mineralys Therapeutics Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Mineralys Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Mineralys Therapeutics Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Mineralys Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.